SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results
SynAct Pharma AB (“SynAct”) today announced additional results from all treated patients in the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency. The study was setup with part 1, where all patients were treated with AP1189, and a part 2, a randomized placebo-controlled study testing AP1189 vs placebo, giving a total of 60 treated patients. In this full dataset, AP1189 treated patients achieved respiratory recovery 4 days quicker than placebo treated patients. A result that was statistically significant. Management is hosting a conference call on